Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: nick nelson who wrote (670)	3/25/1999 8:44:00 PM
From: nick nelson	Read Replies (1) \| Respond to of 975

BLSI... wound a little tighter? viwes.com vs viwes.com Nice pop candidate on any substantial news. FROM WSJ: --------- Article 1 of 50 Boston Life Sciences Sees Big Market For Tumor-Shrinking Drugs 03/17/99 Dow Jones Business News (Copyright (c) 1999, Dow Jones & Company, Inc.) NEW YORK -(Dow Jones)- There will never be too many angiogenic drugs to treat human cancer tumors, Boston Life Sciences Inc. Chief Executive David Hillson said Wednesday in an interview on CNBC. Boston Life Sciences (BLSI) plans to begin testing its Troponin-1 cancer treatment in human clinical trials later this year. EntreMed Inc. (ENMD) has gained a lot of attention in its devlopment of another tumor-shrinking drug angiostatin. On Tuesday, a team of scientists at Duke University reported they may have discovered the mechanism underlying angiostatin, which, like Troponin-1, was discovered by Harvard scientist Judah Folkman. The Wall Street Journal reported that the finding is certain to spur drug giants to seek competing versions of angiostatin, ones that may be less expensive and easier to produce, as well as simpler to use. Both angiostatin and Troponin-1 have shown promise in shrinking tumors in lab animals. But whether either will work in humans remains to be seen. "It is never appropriate to offer false hope to people with suffering with cancer but you have got to make progress and you've got to beat this disease and getting it into human trials will illustrate what its all about," Hillson said. The drugs inhibit angiogenesis - the growth of new blood vessels in the body that a tumor needs to grow and survive. Folkman pioneered the field of so-called antiangiogenesis, and his discoveries have encouraged the development of numerous experimental drugs. Hillson said antiangiogenics offers "extraordinary hope" because it is simpler and more mechanistic than immune system-based approaches to curing cancer. "You have to cut off blood-vessel growth," he said, "and if you do that you may be able to beat the disease." The Boston Life Sciences chief said that there is room for a lot of players in the market for the potential new class of drugs. After researchers better determine if and how such drugs work in humans, "the more the better because of different mechanisms of action," Hillson said. Copyright (c) 1999 Dow Jones & Company, Inc. All Rights Reserved. ---- PS: Are killing and Online Commerce the only games in town? Diversify! nick